Minerva Neurosciences, Inc. cotiza a 2.51 USD y tiene una capitalización bursátil de $120M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms …
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.17 | $-0.17 | $-25.51 | $-0.36 |
| Estimado | $-0.01 | $-0.13 | $-0.30 | $-0.35 |
| Sorpresa | -1600.0% | -30.8% | -8403.3% | -2.9% |
| Métrica | NERV | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -299.5% | -32.0% | -267.5% |
| Current Ratio | 36.28 | 2.84 | +33.44 |
| Debt / Equity | — | 0.28 | — |